Lakewood-Amedex, Inc. is focused on leveraging next-generation antimicrobials to address significant unmet medical needs in the treatment of serious infectious diseases, improving patient outcomes and significantly reducing the urgent threats posed by increasingly antibiotic-resistant bacterial strains.
Lakewood-Amedex is a privately held, clinical stage pharmaceutical company developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called bisphosphocins. The rapid bactericidal action of this novel class of antimicrobials has been demonstrated against more than 70 different bacterial strains so far, including many antibiotic-resistant and biofilm forming bacteria. In the growing crisis of multidrug-resistant infections, Lakewood’s clinical development pipeline is focused on addressing the most life-threatening disease indications.
The Company’s lead therapeutic candidate, Nu-3, a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria, recently completed a Phase 1/2a clinical trial in patients, showing no treatment-related adverse events and a trend toward efficacy. Three additional Phase 2a adaptive arm clinical trials providing robust clinical data in areas of urgent medical need are expected to be completed by 2020.